Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | XBP1 | P17861 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MPI | P34949 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855774 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL6851637 | 0.93 | MEN1 (0.88) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL6851631 | 0.93 | MEN1 (0.88) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL1524476 | 0.89 | MAPT (0.80) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL1524478 | 0.89 | MAPT (0.80) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL24510589 | 0.87 | MAPT (0.76) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL5691813 | 0.85 | MAPT (0.74) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL624663 | 0.85 | MAPT (0.75) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL624662 | 0.85 | MAPT (0.75) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL29644354 | 0.83 | LMNA (0.73) | MAPTMEN1KMT2ALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777447-B2 | ANTIINFLAMMATORY AGENTS, BACTERICIDES, OXIDATION RESISTANCE, ANTICANCER AGENTS | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2004-08-17 | — | — | US | claimed |
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2003-05-15 | — | — | US | claimed |
| US-6777447-B2 | ANTIINFLAMMATORY AGENTS, BACTERICIDES, OXIDATION RESISTANCE, ANTICANCER AGENTS | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2004-08-17 | — | — | US | disclosed |
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GSTK1, GSTP1, CAT | MAPT 3557/4885MEN1 4884/4885KMT2A 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.